Prevention of type 1 diabetes by gene therapy
J. Clin. Invest. Chaorui Tian, et al. 114:969 doi:10.1172/JCI22103 [
Go to this article.]
Figure 5NOD mice reconstituted with either MMP-IAβ-d-GFP_ or MMP-IAβ-k-GFP_transduced bone marrow are protected from diabetes. (
A) NOD mice were reconstituted with bone marrow retrovirally transduced with MMP-IAβ-d-GFP (open circles,
n = 6), MMP-IAβ-k-GFP (×,
n = 6), or control MMP-GFP (filled squares,
n = 6). Shown are the percentages of normoglycemic mice at each time point after bone marrow transplantation. (
B) NOD mice reconstituted with bone marrow retrovirally transduced with either MMP-IAβ-d-GFP or MMP-IAβ-k-GFP are protected from cyclophosphamide-induced diabetes. NOD mice were reconstituted with bone marrow transduced with MMP-IAβ-d-GFP (open circles,
n = 12), MMP-IAβ-k-GFP (×,
n = 12), or control MMP-GFP (filled squares,
n = 14). Twenty-one weeks after bone marrow transplantation, mice were injected intraperitoneally with 200 mg/kg cyclophosphamide. Shown are the percentages of normoglycemic mice at each time point after bone marrow transplantation. Data in
A and
B are the combined results of 2 independent experiments. In all experiments, blood glucose levels were measured weekly.
